Orpheus Contact Letter #2

[Recipient's First Name]:

We at Orpheus Group wish you a speedy recovery. When you have recovered, we hope you will consider a unique opportunity we are prepared to offer you.

As you may know, we are a privately held company specializing in contact with the souls of the recently deceased. Unlike scam artists and local fly-by-night operations, Orpheus Group has had measurable, repeatable success in contacting the dead. The group first entered the public spotlight upon recovering a password protecting US$100M worth of a chemical company's assets after a network engineer suffered a heart attack less than an hour after changing that password. Media attention descended on the Orpheus Group and its CEO, Jack Tilton, playing them first as a novelty segment. Now, as they dug deeper, Orpheus Group is becoming a true success story and a scientific phenomenon.

Mission Statement

Orpheus Group is a customer-driven, profit-focused company with a unique opportunity to expand into a previously untapped marketplace. We base our activities on a four-point strategy articulated by our CEO, Jack Tilton:

• Our people are our uniquely talented greatest resource.
  
• Invest only for real returns.
  
• Attend to our customers' needs and their loved ones' unfinished business efficiently and professionally.
  
• Explore this strange new experience scientifically and responsibly.

We take our responsibility to the bereaved and to the recently departed seriously. Every Orpheus Group representative adheres to a strict code of conduct, ensuring our clients receive a respectful and professional experience. You will not find Orpheus Group commercials on late night cable television, nor Orpheus Group sponsorship of sporting events, no matter how large we grow.

Orpheus Group employs some of the world's leading researchers in physics, cosmology, psychiatry and psychology, and periodically consults with religious officials from across the globe. We are the primary sponsor of the upcoming World Conference on the Afterlife in Breda, The Netherlands.

With all that said, we are a nationwide for-profit corporation, not a funeral home. We don't dress our consultants in black suits or play organ music in the offices. Orpheus Group provides a unique service in the world, and we are the leading corporation in our market space.

History

The Orpheus Group has always been an ambitious organization. Starting from its founding by engineer Bob Jackson and physician Anne Del Greco in 1996, Orpheus Group set out to redefine the way society manages human life and livelihoods.

In those early days, Jackson and Del Greco believed passionately that medical science was on the verge of multiple breakthroughs - the sorts of breakthroughs we see today, with human genetic engineering well along the way to common implementation. Microscopically precise laser surgery allows for previously impossible surgical tasks, and the unlimited promise of stem cell research lays before us. Jackson and Del Greco realized those days were coming and they wanted to provide a unique service: Together, they knew several terminally ill, wealthy individuals who shared the same
optimism about medical science.

Jackson and Del Greco undertook their first cryogenics project while moonlighting from their day jobs. Neither could afford devoting their full energies to human cryogenics in those days, and they used their most eager potential client, Jane Kennedy, as something of a guinea pig. Kennedy, only 37, was suffering from several then-untreatable tumors, but she had robust enough personal assets to provide startup funding for Jackson and Del Greco's early activity under the corporate name JDG Cryogenics. Kennedy was also an adherent of Eastern religion, a viewpoint she says prepared her to accept some important experiences that were yet to come.

Amazingly, five years after Jane Kennedy became JDG Cryogenics' first customer, surgical techniques advanced to the point where her tumors were no longer inoperable. Del Greco scheduled Kennedy's emergence from cryogenic suspension to occur simultaneously with her laparoscopic surgery, engaging some of the finest oncologists in North America.

Kennedy survived, as you may know, and upon her full recovery became one of JDG Cryogenics' greatest supporters. Less well known is the extent to which Jackson and Del Greco relied on Kennedy's trusts to keep JDG Cryogenics operational, When Kennedy emerged from suspended storage, she found herself the owner of a full 25% of JDG Cryogenics, and saw the great possibility of things to come.

Jane Kennedy, as her book The Other Side? describes, was more aware of her environment than she expected to be while cryogenically suspended. The flavor of her frozen coma ebbed and flowed over time, and in at least three incidents, she recalls leaving her body and witnessing the world we know as it changed over the five years of her suspended animation. Kennedy saw and interacted with ghosts while "projecting" and also eavesdropped on conversations throughout the city. When she became conscious, she provided convincing evidence of having witnessed these conversations, often providing details that even the original participants had forgotten about.

Jane Kennedy was not the only early patient to emerge and find themselves with an equity stake. Within seven years after JDG Cryogenics' founding, four others emerged from cryogenic suspension with shares of stock in place of the money they expected to have held in trust. This group - including heart disease survivor George Oliver - hardly acted with a single mind, but they now owned more of the company than did Jackson and Del Greco.

Jane Kennedy convinced the rest of the Board that cryogenics alone would not provide a profit center for this company. She was not the only cryosleep subject who experienced strange hallucinations and astral projection while unconscious, and Kennedy, along with Anne Del Greco, was sure that Kennedy's experiences could somehow generate revenue. With a stroke of the pen, JDG Cryogenics became the Orpheus Group in 2004, named for the Greek mythological character who entered the realm of the dead to free his deceased wife, Eurydice, from torment. Orpheus Group launched a broad and deep study of the afterlife, of post-life entities such as those witnessed by more than one Board member while suspended, and of the precise chemical cocktail enabling them to project their consciousness out into the world while metabolically near death.

We would be remiss if we did not mention the interest, even at this early date, that the United States Federal Government took in the Orpheus Group. When issues of national security are at stake, Orpheus Group is front and center in performing its duty to our country. To the early Orpheus Executive Leadership Team's surprise, the National Security Agency and other groups did not demand a shutdown of the company's activities or any similar government interference in the free market process. Instead, the US Government retains a courtesy seat on the Orpheus Group Board of Directors.

Tragedy struck the Orpheus Group in 2006, with the untimely death of co-founder and Chief Executive Officer Bob Jackson. Jackson, then in his early fifties, suffered a heart attack, leaving the Orpheus Group rudderless and without direction. The days after Bob Jackson's death were difficult for everyone involved with Orpheus Group; for a time it a that the lack of new business, combined with new regulatory difficulties with the Food and Drug Administration, might scuttle the company entirely. Chairman of the Board George Oliver stepped in as Acting CEO while the company searched for a new captain of the ship.

George Oliver continued functioning as acting CEO for almost two full years, until the Board authorized the hiring of Jack Tilton, an energetic young executive from the steel industry, to take Orpheus' helm. Tilton immediately changed Orpheus' direction, bringing in talented executives from many industries to fill key management positions.

Tilton also took a leadership role in a previously understated position. Until 2008, Orpheus had kept below the radar in terms of public relations. The company's services were only affordable by the very wealthy, and Orpheus management had previously been ambivalent about the market value of its post-life projection technology. Tilton turned all this around. He undertook a crusade to raise the company's public image, to make its activities clear to anyone who asked, and he directed Orpheus' scientific staff to publish rigorous papers describing the company's activities and hypotheses around post-life technology.

The mainstream science establishment and press heaped skepticism and even scorn on these early publications, but Orpheus Group persisted, and has since issued continued documented proof to major scientific journals. By 2012, at least two other ventures had formed on the basis of Orpheus' theoretical groundings, and we expect that in two years, post-life technology will become its own unique sector of the economy.

In the years since Jack Tilton raised Orpheus Croup's visibility, our goal has been to refine post-life technology. Our enterprise for doing so has been Project Echo, the secret process by which we train and prepare extraordinary people to project their consciousness onto a higher plane, where they can sense and interact with ghosts. These people function as our Investigative Consultants, and they help to resolve mysteries and ghostly infestations that no one else can handle.

Orpheus Group has been profitable since 2008 and remains a trailblazer in its market sector. Gartner Group, GIGA and Forrester Research all rate Orpheus Group among the market leaders in whichever industry area they choose to categorize us.

You have been contacted because an Orpheus Group representative believes you have a unique talent to contribute to our team, and that together, we can continue to build a successful future.

For more information about Orpheus Group, or to engage our services, please contact a Customer Service Representative.